Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anastrozole.

Expert opinion on drug safety - 1 Nov 2010

Kelly Catherine M, Buzdar Aman U

Abstract excerpt

IMPORTANCE OF THE FIELD: Anastrozole is a third-generation aromatase inhibitor used in the adjuvant setting for the treatment of hormone receptor-positive breast cancer. Several adjuvant randomized trials have reported greater efficacy for anastrozole when compared to tamoxifen. AREAS COVERED IN...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aromatase Inhibitors
Share to Chemotherapy, Adjuvant
Share to Estrogen Antagonists

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nitriles

Share to Postmenopause

Share to Randomized Controlled Trials as Topic

Share to Tamoxifen

Share to Triazoles

Source

Identifiers

PMID: 20923259
DOI: 10.1517/14740338.2010.515977

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20923259-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anastrozole.PMID 20923259Read ↗

The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients.Semantic proximity Read ↗

Pharmacogenomics of third-generation aromatase inhibitors.Semantic proximity Read ↗

A Phase I/II Study of Preoperative Letrozole, Everolimus, and Carotuximab in Stage 2 and 3 Hormone Receptor-positive and Her2-negative Breast Cancer.Semantic proximity Read ↗

Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifenSemantic proximity Read ↗

Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.Semantic proximity Read ↗

Propofol overcome Tamoxifen resistance in breast cancer by modulating tumorogenesis, immune response and metabolismSemantic proximity Read ↗

Rethinking tamoxifen in the management of melanoma: New answers for an old question.Semantic proximity Read ↗

Should you be taking tamoxifen?Semantic proximity Read ↗

Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women.Semantic proximity Read ↗

Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.Semantic proximity Read ↗

Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer.Semantic proximity Read ↗

Oral SERD, A Novel Endocrine Therapy for Estrogen Receptor-Positive Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.